Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00479492 | Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, Volunteers | PHASE2 | COMPLETED | 94 | — | — | Jun 1, 2007 | Jan 1, 2008 | Oct 1, 2009 | 4 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| CP-866,087 | DRUG | 1 mg of CP-866,087, administered QD for 84 days |
| placebo | DRUG | placebo administered QD for 84 days |
Inclusion Criteria: * Body Mass Index (BMI) 30 to 40 kg/m2 and total body weight of \>110 lbs. * Otherwise healthy Exclusion Criteria: * Women must be of non-childbearing potential. * Significant current or history of medical illness.